Diagnostic test utilization: curbing clinical lab waste

It is a direct threat to laboratory throughput, hospital margin, specimen integrity, and diagnostic reliability.

The cost is not limited to the price of reagents. Unnecessary testing consumes analyzer capacity, phlebotomy time, courier runs, accessioning labor, LIS transactions, pathologist review, and clinical attention. Repetitive blood draws can contribute to iatrogenic anemia. Excessive ordering also creates noise around the results that matter.

For laboratory directors and hospital administrators, laboratory diagnostic test utilization management strategies are no longer optional quality initiatives. They are operating controls. The objective is not to make clinicians order fewer tests indiscriminately. The objective is to ensure that each test has a defensible clinical purpose, an appropriate interval, and a workflow capable of delivering a useful result.

The economic and clinical burden of diagnostic overutilization

A laboratory can be busy and still be underperforming. High accession volume often creates the illusion of productivity while hiding a weak contribution margin. When a large share of orders is repetitive, low-value, or poorly timed, the laboratory absorbs the operating cost without generating equivalent clinical value.

The financial impact appears across the diagnostic chain:

• Reagent and consumable expense: Every unnecessary test uses materials, controls, calibrators, tubes, labels, and disposal capacity.
• Instrument utilization: Low-value orders consume analyzer time that could be allocated to urgent, complex, or higher-margin testing.
• Labor demand: Medical laboratory scientists, phlebotomists, accessioning teams, and supervisors process the order regardless of whether the result changes management.
• Specimen logistics: Additional draws increase transport events, accessioning volume, storage requirements, and opportunities for misidentification or rejection.
• Clinical review burden: Physicians and care teams must interpret more results, including borderline abnormalities with no actionable significance.
• Revenue cycle friction: Unclear medical necessity, duplicate orders, and payer scrutiny create avoidable denial and reconciliation work.

The laboratory does not control all of these costs through pricing. It controls them through utilization design.

Low-value care in the United States has been estimated to cost approximately $800 billion annually. Laboratory testing is one component of that wider problem, but it is unusually well positioned for intervention because ordering patterns can be measured, rules can be embedded in the LIS or electronic health record, and changes can be monitored at service-line level.

The clinical consequences are equally material. Repetitive daily laboratory testing in clinically stable hospitalized patients has been associated with iatrogenic anemia in an estimated 20% of hospitalized patients. The laboratory is not the sole cause. The ordering pattern reflects clinical habits, protocol design, staffing models, defensive medicine, and the structure of reimbursement. But the laboratory is often the only department with the data and technical authority to expose the pattern clearly.

Utilization management is not a campaign to reduce volume. It is a control system for directing laboratory capacity toward tests that can change care.

The operational distinction matters. A blanket reduction target can damage access and create resistance. A targeted utilization program improves the mix of work. It removes repetition where repetition adds no value, while protecting time-sensitive and clinically justified testing.

Systemic drivers behind poor clinical lab test ordering patterns

The common explanation is that clinicians order too many tests. That is incomplete and operationally unhelpful.

Ordering behavior is shaped by the system around the clinician. If a default order set includes daily complete blood counts and metabolic panels, those tests become routine. If the EHR makes a repeat order easier than reviewing the prior result, repetition becomes the path of least resistance. If turnaround-time expectations are poorly defined, clinicians may order multiple tests to compensate for uncertainty. If fee-for-service incentives reward activity, the system may create volume pressure even when no individual intends to provide low-value care.

Several drivers appear repeatedly in laboratory utilization reviews.

Default frequency creates automatic demand

Daily testing is frequently treated as a neutral default. It is not neutral. A daily default converts a clinical decision into a recurring transaction. Unless the ordering system requires reassessment, the test continues after the patient’s condition, treatment, or risk profile has changed.

This is particularly problematic in stable inpatients and chronic-care populations. The first result may have been clinically useful. The fourth consecutive result may not be.

Order sets conceal the cost of individual tests

Order sets improve standardization, but they can also bundle tests that are not required for every patient. The problem is not the existence of order sets. The problem is the absence of governance over their content, ownership, and review cycle.

A set that was appropriate during an earlier clinical protocol can remain active long after evidence, reimbursement, or workflow has changed. It then becomes a silent source of demand.

Defensive medicine expands the testing perimeter

Diagnostic uncertainty is real. So are malpractice concerns. The OECD has identified diagnostic errors as the most common reason for medical negligence claims in primary and ambulatory settings, affecting an estimated 12 million U.S. adults. That environment encourages caution, and caution can become indiscriminate testing.

The answer is not to dismiss the risk. It is to distinguish between testing that reduces meaningful uncertainty and testing that merely creates more data. A larger result set does not automatically produce a safer diagnosis. In some cases, it increases the chance that an incidental or borderline finding will trigger unnecessary follow-up.

Fragmented information drives duplicate testing

Patients move between emergency departments, inpatient units, outpatient clinics, reference laboratories, and external providers. When prior results are difficult to locate, clinicians may repeat testing rather than spend time resolving the information gap.

This is an information architecture problem. It cannot be solved by reminders alone. The LIS, EHR, interface engine, and reporting layer must make recent relevant results visible at the point of ordering.

Molecular testing requires a different utilization discipline

Molecular lab utilization review is especially important because molecular assays can carry higher reagent costs, specialized staffing requirements, longer validation obligations, and significant interpretation demands. A duplicate chemistry result may be inconvenient. A poorly timed molecular test can consume scarce capacity and produce a result that is uninterpretable because the specimen, treatment status, or disease phase is wrong.

Pathology laboratories should therefore avoid treating molecular utilization as a generic version of routine chemistry utilization. The review must account for specimen type, prior testing, treatment exposure, assay eligibility, and the clinical question the test is intended to answer.

The operating framework for laboratory stewardship

Laboratory stewardship programs borrow from antibiotic stewardship, but the management model is broader than a list of restricted tests. A durable program requires governance, intervention design, data extraction and monitoring, and continual assessment.

The framework should be owned jointly by laboratory leadership and clinical operations. A laboratory-only program will be viewed as a cost-cutting exercise. A clinically disconnected medical staff committee will lack the technical detail required to build workable controls. Both sides must be accountable.

Governance comes first

The governance structure should define:

• Which executive owns the program and resolves cross-department conflicts.
• Which laboratory director or utilization lead controls the technical agenda.
• Which clinical services participate in rule development.
• How exceptions are approved and documented.
• How frequently order sets and utilization rules are reviewed.
• Which metrics are reported to department chairs, nursing leadership, finance, and quality committees.

Governance also determines whether the program can act on findings. A dashboard that identifies repeat testing but cannot change an order set is not a management system. It is an observation tool.

Interventions must match the failure mode

Different problems require different controls. A hard stop may be appropriate for a clear duplicate order. It may be inappropriate for a test where the clinical context is variable and urgent exceptions are common.

Common intervention types include:

1. Duplicate-order alerts. The EHR or LIS flags an existing result or active order within a defined interval. The alert should display the relevant result, not merely state that duplication exists.

2. Minimum interval guidance. The ordering interface shows an expected interval for repeat testing based on the assay and clinical use case.

3. Reflex testing. A secondary test is performed only when the initial result meets a defined condition. This reduces unnecessary separate orders and improves workflow consistency.

4. Order-set redesign. Tests with low clinical value are removed from default bundles or moved into optional selections requiring an explicit choice.

5. Approval pathways. Selected high-cost, high-complexity, or highly specialized assays require review by laboratory medicine, pathology, or a designated clinical service.

6. Prospective consultation. Clinicians receive assistance before testing when the question, specimen, or timing is unclear.

7. Retrospective feedback. Departments receive utilization reports that compare ordering patterns, repeat intervals, and exception rates.

The strongest programs combine decision support with professional feedback. Alerts alone create fatigue. Reports alone arrive too late. A control system needs both real-time intervention and periodic management review.

Continual improvement must be measurable

A laboratory stewardship program should not be judged by gross test volume alone. A decline in orders could indicate improved practice, reduced access, delayed diagnosis, or a change in patient mix. The metric must be tied to clinical purpose and operational impact.

Useful measures include:

The key is segmentation. A hospital-wide average can conceal a problem in one unit or assay family. Reporting should distinguish emergency, inpatient, outpatient, oncology, critical care, surgical pathology, and molecular testing where the workflow and clinical risk differ.

Data-driven interventions for reducing unnecessary diagnostic testing

Utilization management begins with a credible baseline. Before changing rules, the laboratory must understand who orders what, at which frequency, for which patient populations, and with what operational consequence.

The data should connect the clinical order to the laboratory event. That requires more than a billing report. A useful analysis combines EHR ordering data, LIS accession and result data, specimen timestamps, cancellation records, analyzer utilization, and, where possible, downstream clinical indicators.

A practical analysis sequence is:

1. Define the target test or panel. Start with a limited number of high-volume or high-cost opportunities. Broad programs lose focus and make attribution difficult.

2. Map the current workflow. Document the order path, default frequency, collection process, approval requirements, result delivery, and billing behavior.

3. Measure repetition. Identify orders placed within short intervals, including duplicates across locations or interfaces.

4. Segment by clinical context. Separate intensive care from general medicine, oncology from primary care, and acute evaluation from routine monitoring.

5. Identify variation. Compare services with similar patient populations. Large differences often indicate a process problem rather than a clinical necessity.

6. Estimate operational impact. Quantify analyzer minutes, staff time, specimen volume, reagent use, and redraws associated with the target pattern.

7. Design the intervention. Select an alert, order-set change, interval rule, consultation model, or reporting approach.

8. Pilot before scaling. Test the intervention in one service line and monitor clinical exceptions.

9. Review after implementation. Measure volume, safety, provider behavior, TAT, and financial impact. Then revise the rule.

The financial model should include avoided cost and retained capacity. A canceled test does not always equal savings if the analyzer remains idle and staffing cannot be adjusted. The stronger business case may be capacity released for urgent molecular assays, reduced overtime, fewer recollections, or lower denial exposure.

Build rules that respect clinical context

A minimum interval rule should not be treated as an absolute clinical truth. It is a decision-support boundary. The workflow must allow exceptions for deterioration, treatment changes, transfusion, surgery, bleeding, renal injury, sepsis evaluation, and other conditions where repeat testing is justified.

The order interface should ask for a reason only when the exception is clinically meaningful. Excessive justification fields create workarounds and inaccurate selections. A concise reason list, combined with periodic review of override behavior, is more effective than a long form.

The same principle applies to molecular testing. A test may be appropriate after a new clinical event but not as a routine repeat. The interface should surface the prior result, specimen date, assay type, and relevant status information. It should not force the clinician to reconstruct that history manually.

Use feedback without turning it into surveillance theater

Provider reports should be operationally useful. A department that receives a ranking without context will usually treat it as a financial penalty. A department that receives its repeat-testing rate, peer range, exception profile, and the specific order-set behavior driving the pattern has a basis for action.

Feedback should identify:

• The test categories generating the largest volume of low-value repeats.
• The units or order sets responsible for the pattern.
• The number of canceled or avoided tests after intervention.
• The number and nature of overrides.
• Any effect on TAT, specimen rejection, or critical-result communication.
• The next process change required.

The laboratory should avoid attributing overutilization exclusively to individual clinicians. System defaults, fragmented records, staffing pressure, reimbursement incentives, and defensive practice are usually part of the causal chain. Accountability remains necessary, but the intervention must address the mechanism that produces the behavior.

Protecting patient safety while reducing volume

The most important objection to utilization management is straightforward: fewer tests could mean missed disease.

That risk is real if the program uses crude volume targets. It is manageable when the program is designed around clinical value, exception handling, and surveillance.

Diagnostic stewardship in pathology should therefore be treated as a safety discipline. The question is not whether a test was ordered. The question is whether the test was ordered at the right time, on the right specimen, for the right clinical question, and with a reporting process that supports action.

Several safeguards should be mandatory.

Preserve urgent access

Hard stops should never block emergency or time-critical testing without a rapid override. The override should be visible in the audit trail and reviewed in aggregate, not used as a barrier that delays care.

Monitor for delayed diagnosis

Utilization changes should be linked to quality surveillance. Depending on the service, that may include critical-result rates, amended reports, repeat emergency visits, escalation to higher care, unexpected transfusion, or delayed treatment initiation.

Not every clinical event can be attributed to laboratory utilization. The purpose is not to create false precision. It is to identify signals that require investigation.

Control the preanalytical consequences

Reducing unnecessary orders can lower specimen volume, but poorly designed interventions can also create more redraws. If a clinician cancels a test and later reorders it because the first specimen was inadequate, the program has failed operationally.

The laboratory should monitor order-to-collection conversion, recollection rate, specimen rejection, and time from collection to accessioning. Utilization management and preanalytical quality control belong in the same performance discussion.

Maintain chain of custody and result traceability

Every intervention must preserve the specimen chain of custody and the integrity of the result record. If an order is modified, canceled, reflexed, or redirected, the LIS should retain a clear audit trail. This is a compliance requirement and a practical defense against disputes about what was ordered and performed.

The same discipline applies when testing is referred externally. The laboratory must know which entity performed the assay, how the result returned, whether the report was integrated correctly, and whether the clinical record reflects the final interpretation.

The financial case for disciplined utilization

Laboratory administrators should present utilization management as a margin and capacity program, not merely as a quality initiative. The case is strongest when operational savings are tied to measurable constraints.

A disciplined program can produce value through several channels:

• Lower reagent and consumable consumption.
• Fewer unnecessary phlebotomy events and recollections.
• Reduced overtime caused by avoidable volume peaks.
• More predictable analyzer loading.
• Better access to high-complexity and urgent testing.
• Lower denial risk where medical necessity documentation improves.
• Reduced manual review and exception handling.
• Improved compliance with internal policies and accreditation expectations.
• Stronger evidence for capital planning and staffing decisions.

The laboratory should calculate the cost of intervention as well. Building an alert, revising an order set, validating a rule, educating clinicians, and maintaining reports all require resources. A program that generates savings on paper while creating permanent administrative overhead has not improved the operating model.

Contribution margin analysis should be performed at the assay or service-line level where feasible. High-volume routine tests may have a low unit cost but consume substantial aggregate labor and capacity. Low-volume molecular tests may have higher unit economics but require strict scheduling and specimen controls. The strategic question is not simply which tests are expensive. It is which testing patterns consume constrained resources without producing proportional clinical value.

A management agenda for the next operating cycle

Laboratory directors do not need to wait for a large enterprise transformation. The first phase can be narrow and disciplined.

A practical agenda includes:

1. Select two or three test categories with high repeat volume, high cost, or visible clinical variation.

2. Establish a baseline using LIS, EHR, and operational data rather than billing volume alone.

3. Assign an executive owner and a clinical-laboratory governance group.

4. Review the relevant order sets and default frequencies.

5. Build a minimum-interval or duplicate-order intervention with a documented exception path.

6. Pilot the intervention in one service line.

7. Track utilization, TAT, overrides, recollections, safety signals, and financial effect.

8. Report results to clinical leadership in operational terms.

9. Revise the rule based on actual exception patterns.

10. Scale only after the intervention demonstrates both utilization improvement and clinical safety.

This sequence is deliberately conservative. It avoids the common failure mode of launching a hospital-wide campaign before the laboratory understands its own data. It also creates a defensible compliance record: the organization can show what changed, why it changed, how exceptions were handled, and what happened afterward.

The laboratory cannot afford unmanaged demand

Diagnostic overutilization is not solved by asking clinicians to be more careful. That is an education tactic, not an operating strategy. Durable improvement requires governance, reliable data, workflow controls, and continuous review.

The laboratory is central to this work because it sits at the intersection of clinical decision-making, regulatory compliance, specimen logistics, reimbursement, and capacity planning. It can see patterns that individual clinicians cannot. It can identify where repetition begins, where order sets amplify demand, and where unnecessary testing creates downstream risk.

The objective is not a smaller laboratory. It is a more controlled one: fewer non-contributory orders, better use of instruments and staff, stronger preanalytical quality, and faster access to testing that changes care.

Executives should treat unmanaged utilization as an operating liability. If the laboratory cannot explain its major ordering patterns, defend its repeat-testing rules, and demonstrate the effect of its interventions, it does not have utilization management. It has volume.

That distinction will determine whether diagnostic services improve margin and clinical reliability—or continue paying for activity that does not advance patient care.